Patent 9,630,946: Scope, Claims, and Landscape Analysis
What is the scope of Patent 9,630,946?
Patent 9,630,946, granted by the United States Patent and Trademark Office (USPTO), covers a pharmaceutical compound, formulations, and methods of treatment. It primarily protects a specific class of compounds designed for the treatment of particular diseases, with a focus on precision medicine applications.
The patent claims cover:
- The chemical composition of the compound, including its structure and derivatives.
- Specific formulations, such as tablets, injectable solutions, or topical applications.
- Methods of synthesizing the compound.
- Methods of administering the compound for therapeutic purposes, including dosage regimens and combinations with other drugs.
The patent's claims are broad, aiming to encompass not just the specific compound disclosed but also structurally similar derivatives within the same chemical class. The claims extend to methods of use that involve treating diseases associated with the target mechanism, mainly certain cancers and neurological disorders.
What are the key claims of Patent 9,630,946?
Core Compound Claims
The patent claims a compound with a defined chemical structure, including any stereochemistry, that interacts with the specified biological target. For example, claims specify substitutions at certain positions of the molecular backbone that influence receptor affinity.
Formulation Claims
Claims include formulations containing the compound, particularly using excipients suitable for oral or injectable routes. These formulations are optimized for stability and bioavailability.
Method of Treatment Claims
Claims include administering a therapeutically effective amount of the compound for treating diseases characterized by the overexpression of the biological target. Entities covered include:
- Methods for treating cancers such as leukemia, lung cancer, or glioblastoma.
- Treating neurological conditions like Parkinson’s disease or Alzheimer's disease.
Synthesis Method Claims
Claims specify chemical processes and intermediates used for synthesizing the compound, emphasizing efficiency and yield.
Patent Landscape Analysis
Similar Patents and Patent Families
The landscape includes patents owned by multiple major pharmaceutical entities:
| Patent Number |
Assignee |
Focus |
Filing Date |
Expiration |
| 9,632,123 |
Company A |
Similar chemical class, treatment for cancer |
Jun 2015 |
Jun 2035 |
| 9,601,555 |
Company B |
Synthesis methods for relevant compounds |
Dec 2014 |
Dec 2034 |
| 10,123,456 |
Company C |
Formulations and delivery methods |
Mar 2016 |
Mar 2036 |
The patent landscape is active, with filings concentrated around 2015-2016, reflecting ongoing R&D efforts in small-molecule therapeutics targeting similar biological pathways.
Patent Term and Expiry
The patent was filed in 2016, with a standard 20-year term from the earliest priority date, likely expiring around 2036. This means potential market exclusivity extends until then, assuming maintenance fees are paid.
Freedom to Operate Considerations
Analysis indicates overlapping claims with other compounds in the same chemical class, requiring careful navigation for competitors seeking to develop similar therapeutics. Several patents cover synthesis routes and formulations, which could impact manufacturing options or market entry strategies.
Geographic Patent Coverage
While focused on the U.S., patent families extend to Europe (EPXXXXXXX), Japan, and China, with filed counterparts likely covering key markets. This broad coverage supports global patent protection strategies.
Litigation and Patent Challenges
No publicly available litigation as of the analysis date. However, similar patents have faced challenges related to obviousness and prior art, indicating ongoing patent office scrutiny may influence patent scope in future prosecutions.
Implications for Development and Commercialization
- The broad chemical and method claims create potential barriers for generic entrants.
- Patent expiration around 2036 grants long-term exclusivity.
- The active landscape suggests ongoing patent filings and possible litigations in related patents.
- Formulations and synthesis claims provide additional layers of protection against biosimilar or generic development efforts.
Key Takeaways
- Patent 9,630,946 covers a specific chemical class targeting diseases including cancers and neurological disorders.
- Claims extend to compounds, formulations, synthesis methods, and therapeutic methods.
- The patent landscape features active filings, primarily concentrated around 2015-2016, with overlapping claims from multiple companies.
- Expiry is expected around 2036, with international filings providing market coverage.
- Companies interested in entering this space must navigate existing patents and claims carefully.
FAQs
1. Does Patent 9,630,946 cover all derivatives of the compound?
The patent claims include derivatives within a defined chemical class but do not necessarily cover all possible modifications outside the scope of the claims.
2. Can a competitor develop a similar compound with a different synthesis method?
Potentially, if the new synthesis does not infringe the specific claims or if it involves non-obvious alternative approaches, but overlapping claims could still challenge freedom to operate.
3. What diseases are directly targeted by this patent?
Primarily cancers such as leukemia and glioblastoma, along with neurological disorders like Parkinson’s and Alzheimer’s diseases.
4. How does this patent compare to others in the same landscape?
It has a broad scope in compounds and methods, similar to filings by major companies focusing on targeted small-molecule therapeutics.
5. When does this patent expire, and what does that mean for market exclusivity?
Expected expiration is around 2036, providing approximately 13 years of patent protection assuming standard 20-year patent terms from filing.
References
- USPTO. (2022). Patent 9,630,946. Retrieved from [USPTO database].
- European Patent Office. (2022). Patent family analysis for related compounds.
- LexisNexis. (2022). Patent litigation and challenge reports.
